دورية أكاديمية
أعرض في EDS

At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant.

التفاصيل البيبلوغرافية
العنوان: At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant.
المؤلفون: Singanallur NB; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness (ACDP), Geelong, VIC, Australia., van Vuren PJ; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness (ACDP), Geelong, VIC, Australia., McAuley AJ; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness (ACDP), Geelong, VIC, Australia., Bruce MP; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness (ACDP), Geelong, VIC, Australia., Kuiper MJ; Data61, Commonwealth Scientific and Industrial Research Organisation (CSIRO), Docklands, VIC, Australia., Gwini SM; University Hospital Geelong, Barwon Health, Geelong, VIC, Australia., Riddell S; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness (ACDP), Geelong, VIC, Australia., Goldie S; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness (ACDP), Geelong, VIC, Australia., Drew TW; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness (ACDP), Geelong, VIC, Australia., Blasdell KR; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness (ACDP), Geelong, VIC, Australia., Tachedjian M; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness (ACDP), Geelong, VIC, Australia., Mangalaganesh S; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness (ACDP), Geelong, VIC, Australia.; Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia., Chahal S; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness (ACDP), Geelong, VIC, Australia., Caly L; Victorian Infectious Diseases Reference Laboratory (VIDRL), The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia., Druce JD; Victorian Infectious Diseases Reference Laboratory (VIDRL), The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia., Juno JA; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia., Kent SJ; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia., Wheatley AK; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia., Vasan SS; Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness (ACDP), Geelong, VIC, Australia.
المصدر: Frontiers in immunology [Front Immunol] 2022 May 17; Vol. 13, pp. 883612. Date of Electronic Publication: 2022 May 17 (Print Publication: 2022).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مواضيع طبية MeSH: COVID-19*/prevention & control , Viral Vaccines*, COVID-19 Vaccines ; Humans ; SARS-CoV-2 ; Vaccines, Inactivated
مستخلص: Plasma samples taken at different time points from donors who received either AstraZeneca (Vaxzevria) or Pfizer (Comirnaty) or Moderna (Spikevax) coronavirus disease-19 (COVID-19) vaccine were assessed in virus neutralization assays against Delta and Omicron variants of concern and a reference isolate (VIC31). With the Pfizer vaccine there was 6-8-fold reduction in 50% neutralizing antibody titres (NT 50 ) against Delta and VIC31 at 6 months compared to 2 weeks after the second dose; followed by 25-fold increase at 2 weeks after the third dose. Neutralisation of Omicron was only consistently observed 2 weeks after the third dose, with most samples having titres below the limit of detection at earlier timepoints. Moderna results were similar to Pfizer at 2 weeks after the second dose, while the titres for AstraZeneca samples derived from older donors were 7-fold lower against VIC31 and below the limit of detection against Delta and Omicron. Age and gender were not found to significantly impact our results. These findings indicate that vaccine matching may be needed, and that at least a third dose of these vaccines is necessary to generate sufficient neutralising antibodies against emerging variants of concern, especially Omicron, amidst the challenges of ensuring vaccine equity worldwide.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2022 Singanallur, van Vuren, McAuley, Bruce, Kuiper, Gwini, Riddell, Goldie, Drew, Blasdell, Tachedjian, Mangalaganesh, Chahal, Caly, Druce, Juno, Kent, Wheatley and Vasan.)
References: ILAR J. 2021 Dec 31;62(1-2):48-59. (PMID: 35022734)
Emerg Microbes Infect. 2021 Dec;10(1):629-637. (PMID: 33691606)
NPJ Vaccines. 2021 May 10;6(1):67. (PMID: 33972565)
Lancet Respir Med. 2022 Feb;10(2):e19. (PMID: 35030317)
J Chem Phys. 2020 Jul 28;153(4):044130. (PMID: 32752662)
N Engl J Med. 2022 Mar 17;386(11):1046-1057. (PMID: 35081293)
Nature. 2021 Aug;596(7873):583-589. (PMID: 34265844)
Elife. 2020 Apr 02;9:. (PMID: 32228860)
N Engl J Med. 2021 Jun 3;384(22):2092-2101. (PMID: 33835769)
Viruses. 2022 Apr 13;14(4):. (PMID: 35458530)
Transbound Emerg Dis. 2020 Jul;67(4):1453-1462. (PMID: 32306500)
J Membr Biol. 2006;211(3):139-50. (PMID: 17091214)
Bull World Health Organ. 2020 Jul 01;98(7):495-504. (PMID: 32742035)
BMC Evol Biol. 2004 Jun 28;4:21. (PMID: 15222897)
Sci Transl Med. 2021 Aug 18;13(607):. (PMID: 34315826)
PLoS Pathog. 2022 Jan 13;18(1):e1010161. (PMID: 35025969)
N Engl J Med. 2022 Feb 17;386(7):698-700. (PMID: 35021005)
N Engl J Med. 2022 Feb 10;386(6):599-601. (PMID: 35030645)
N Engl J Med. 2022 Apr 7;386(14):1377-1380. (PMID: 35297591)
J Chem Inf Model. 2022 Feb 14;62(3):627-631. (PMID: 35072475)
ACS Infect Dis. 2021 Aug 13;7(8):2546-2564. (PMID: 34260218)
NPJ Vaccines. 2020 Oct 8;5:96. (PMID: 33083031)
Nature. 2022 Feb;602(7898):676-681. (PMID: 35016198)
Nature. 2022 Mar;603(7902):715-720. (PMID: 35104836)
J Virol. 2010 Oct;84(19):9733-48. (PMID: 20660197)
فهرسة مساهمة: Keywords: AlphaFold; COVID-19; SARS-CoV-2; biomolecular modelling; neutralising antibody titres; spike protein; vaccines; variants of concern
المشرفين على المادة: 0 (COVID-19 Vaccines)
0 (Vaccines, Inactivated)
0 (Viral Vaccines)
SCR Organism: SARS-CoV-2 variants
تواريخ الأحداث: Date Created: 20220603 Date Completed: 20220606 Latest Revision: 20220716
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC9152325
DOI: 10.3389/fimmu.2022.883612
PMID: 35655773
قاعدة البيانات: MEDLINE
الوصف
تدمد:1664-3224
DOI:10.3389/fimmu.2022.883612